IP Library Granted Patent US 11,110,210
Granted Patent B2
US 11,110,210 · App. 17/075,572 · Granted Sep 7, 2021

Self-expanding devices and methods therefor

Inventors: Donald J. Eaton (Los Altos, CA); Bin Huang (Pleasanton, CA); Anthony J. Abbate (Santa Clara, CA); Gail M. Zaler (Milpitas, CA); David C. Gale (Kennesaw, GA)
Assignee: Intersect ENT, Inc.
A61L31/022A61B17/24A61B17/3468A61B17/3478A61F2/04A61F2/18A61F2/82A61F2/86A61F2/89A61F2/95A61F5/08A61K9/70A61L31/10A61L31/148A61L31/16A61M29/00A61B2017/3454A61F2/186A61F2/9522A61F2/9524A61F2002/048A61F2002/91508A61F2210/0004A61F2210/0076A61F2220/005A61F2220/0058A61F2230/0091A61F2240/001A61F2250/003A61F2250/006A61F2250/0067
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,110,210
App. No.
17/075,572
Granted
Sep 7, 2021
Kind
B2
Abstract

Described here are delivery devices for delivering one or more implants to the body, and methods of using. The delivery devices may deliver implants to a variety of locations within the body, for a number of different uses. In some variations, the delivery devices have a cannula with one or more curved sections. In some variations, a pusher may be used to release one or more implants from the cannula. In some variations, one or more of the released implants may be a self-expanding device. Methods of delivering implants to one or more sinus cavities are also described here.

Claims (14)

1. A method of treating one or more sinus conditions in a patient, the method comprising:

dilating a paranasal sinus region with an expandable balloon, wherein an expandable device is detachably coupled around the expandable balloon;

delivering the expandable device to the dilated paranasal sinus region, wherein the expandable device disengages from the expandable balloon, wherein the expandable device is configured to expand from a first compressed configuration to a second expanded configuration for conformation against sinus tissue, and wherein the expandable device is at least partially coated with a drug eluting layer comprising a drug, the drug eluting layer configured to release the drug at a daily dosage of about 500 μg or less per day; and

withdrawing the expandable balloon from the paranasal sinus region after dilation.

2. The method of claim 1 , wherein the expandable device comprises one or more biodegradable polymer filaments arranged to form repeating diamond-shaped pattern and wherein a distal end of the expandable device and a proximal end of the expandable device are defined by each of the diamond shapes.

3. The method of claim 1 , wherein the expandable device is self-expanding.

4. The method of claim 1 , wherein the expandable device has a compressed diameter in the first compressed configuration and an expanded diameter in the second expanded configuration, and wherein the ratio of the expanded diameter to the compressed diameter is from about 2:1 to about 20:1.

5. The method of claim 1 , wherein the drug comprises a therapeutic agent comprising one or more selected from the group consisting of: anti-inflammatory agents, anti-allergens, antibiotics, anti-cholinergic agents, antihistamines, anti-infectives, anti-platelet agents, anti-coagulants, antithrombic agents, anti-scarring agents, anti-proliferative agents, chemotherapeutic agents, anti-neoplastic agents, decongestants, healing promoting agents, vitamins, hyperosmolar agents, immunomodulators, and immunosuppressive agents.

6. The method of claim 5 , wherein the drug is an anti-inflammatory agent that comprises mometasone furoate, fluticasone propionate, or both.

7. The method of claim 1 , wherein the drug eluting layer is configured to release the drug over a period of time between about 5 days to about 120 days.

8. The method of claim 1 , wherein the drug eluting layer comprises a release rate modifier.

9. The method of claim 1 , wherein delivering the expandable device comprises delivering the expandable device to an ethmoid sinus cavity or ostium, a maxillary sinus cavity or ostium, a frontal sinus cavity or ostium, a sphenoid sinus cavity or ostium, or an osteomeatal complex.

10. The method of claim 1 , wherein the one or more biodegradable polymer filaments comprise poly-(lactide-co-glycolide).

11. The method of claim 1 , wherein the one or more biodegradable polymer filaments comprise paclitaxel.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2020
From: EATON, DONALD J.; HUANG, BIN; ABBATE, ANTHONY J.; ZALER, GAIL MEREDITH; GALE, DAVID
To: SINEXUS, INC.
Reel/Frame 054116/0381 →
CHANGE OF NAME Recorded Oct 20, 2020
From: SINEXUS, INC.
To: INTERSECT ENT, INC.
Reel/Frame 054156/0914 →
Continuity (8)
Continuation 16727345 · Dec 26, 2019
Continuation 16588294 · Sep 30, 2019
Continuation 16021659 · Jun 28, 2018
Continuation 14081974 · Nov 15, 2013
Continuation 12334373 · Dec 12, 2008
Provisional Application 61058803 · Jun 4, 2008
Provisional Application 61014653 · Dec 18, 2007
Related Publication 20210030927A1 · Feb 4, 2021